Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Glucosamine Fails to Relieve Back Pain - Nutraceuticals World

What are you searching for?

Sign in
Market Updates

Glucosamine Fails to Relieve Back Pain

Glucosamine proved to be ineffective in relieving lower back pain, according to a study published in the Journal of the American Medical Association (JAMA).

Author Image

By: Sean Moloughney

Editor, Nutraceuticals World

Glucosamine proved to be ineffective in relieving lower back pain, according to a study published in the Journal of the American Medical Association (JAMA).

 
This randomized, double-blind, placebo-controlled trial was conducted at Oslo University Hospital Outpatient Clinic, Oslo, Norway, with 250 patients older than 25 years of age with chronic low back pain (LBP) (greater than 6 months) and degenerative lumbar osteoarthritis (OA).
 
Subjects received 1500 mg of oral glucosamine (n = 125) or placebo (n = 125) dairly for 6 months, with assessment of effect after the 6-month intervention period and at 1 year (6 months postintervention).
 
The primary outcome was pain-related disability measured with the Roland Morris Disability Questionnaire (RMDQ). Secondary outcomes were numerical scores from pain-rating scales of patients at rest and during activity, and the quality-of-life EuroQol-5 Dimensions (EQ-5D) instrument. Data collection occurred during the intervention period at baseline, 6 weeks, 3 and 6 months, and again 6 months following the intervention at 1 year. Group differences were analyzed using linear mixed models analysis.
 
At baseline, mean RMDQ scores were 9.2 for glucosamine and 9.7 for the placebo group. At 6 months, the mean RMDQ score was the same for the glucosamine and placebo groups (5.0). At 1 year, the mean RMDQ scores were 4.8 for glucosamine and 5.5 for the placebo group. No statistically significant difference in change between groups was found when assessed after the 6-month intervention period and at 1 year.

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Add Nutraceuticals World as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters